Why now?
Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fueled increased investment and pharmaceutical interest in the CNS, making it a top three area for drug approvals in the last decade.
With AbbVie, BMS, and Lundbeck making major acquisitions in the last 12 months alone, this wave of deal-making is redemption for biotech who kept the lights on and are building with greater strength than before.
With no dominant target, modality, or disease leading the way, partnerships across technologies or best-in-class assets are an opportunity for all.
Unite with 40%+ C-level and 94% Director or above* decision makers in a hyper-aligned critical mass; as the Neuroscience Innovation Pharma Partnering Summit brings on-scope and in-strategy companies together.
"This event was more focused than BIO. Plenty of opportunities to bump into people and many of the pharma companies made themselves available. We felt that we got much more traction at this event than at BIO"
CEO attendee, ADC & Radiopharmaceuticals Pharma Partnering Summit, September 2024
Looking to invest, acquire, license, or partner?
EVENT IN NUMBERS
Laying enabled partnering on top of hyper-relevant scientific discussion so that pharma can contextualize and compare, and biotech can have guaranteed face-to-face meetings with the right, current contacts.
C-level or senior level attendees from over 60 companies
private meeting slots across two days
networking, from candid interactions to pre-scheduled meetings
alignment with all attendees increasing hit-rate and efficiency of networking
Testimonials
The focused niche really increased the impact for us overall. Thanks for including us in the program
David Dowling, Global Search & Evaluation Lead, Pharma Partnering, Roche
It was stellar; I heard this sentiment echoed throughout. We appreciated the focused yet expansive discussions, and talks in a more intimate setting allowing for easier networking, too
Kilang Yanger, Associate Director, Business Development Seach & Evaluation, BMS
I thought it was fantastic – operationally excellent and thoughtfully designed
Albert Hsia, Executive Director, Business Development, Merck
It was a great group of high-quality companies/people in the perfect setting
Melissa Conner, Senior Director of Acquisitions & Licensing, J&J